Open Access

[Corrigendum] RNA interference‑mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells

  • Authors:
    • Tao Liu
    • Yixiang Liao
    • Huangheng Tao
    • Jinmin Zeng
    • Gang Wang
    • Zhonghua Yang
    • Yongzhi Wang
    • Yu Xiao
    • Jiajie Zhou
    • Xinghuan Wang
  • View Affiliations

  • Published online on: January 26, 2022     https://doi.org/10.3892/ol.2022.13211
  • Article Number: 91
  • Copyright : © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

View Figures

Related Articles

Journal Cover

March-2022
Volume 23 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu T, Liao Y, Tao H, Zeng J, Wang G, Yang Z, Wang Y, Xiao Y, Zhou J, Wang X, Wang X, et al: [Corrigendum] RNA interference‑mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells. Oncol Lett 23: 91, 2022
APA
Liu, T., Liao, Y., Tao, H., Zeng, J., Wang, G., Yang, Z. ... Wang, X. (2022). [Corrigendum] RNA interference‑mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells. Oncology Letters, 23, 91. https://doi.org/10.3892/ol.2022.13211
MLA
Liu, T., Liao, Y., Tao, H., Zeng, J., Wang, G., Yang, Z., Wang, Y., Xiao, Y., Zhou, J., Wang, X."[Corrigendum] RNA interference‑mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells". Oncology Letters 23.3 (2022): 91.
Chicago
Liu, T., Liao, Y., Tao, H., Zeng, J., Wang, G., Yang, Z., Wang, Y., Xiao, Y., Zhou, J., Wang, X."[Corrigendum] RNA interference‑mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells". Oncology Letters 23, no. 3 (2022): 91. https://doi.org/10.3892/ol.2022.13211